Telix Pharmaceuticals (ASX: TLX) — Company Overview, News & Financial Data
Telix Pharmaceuticals develops diagnostic and therapeutic radiopharmaceuticals for oncology and rare diseases, focusing on precision treatment.
Telix Pharmaceuticals
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted radiopharmaceuticals for cancer imaging and therapy. The company utilizes a theranostic approach that pairs diagnostic imaging agents with therapeutic radiopharmaceutical candidates to precisely locate and treat disease. Its clinical pipeline and commercial offerings span urologic oncology, neurologic oncology, and other solid tumors. Telix operates an international manufacturing, supply, and distribution network, alongside integrated medical technology solutions, software, and artificial intelligence tools to support precision medicine across global markets.
Snapshot
Operations
Products and/or services of Telix Pharmaceuticals
- Prostate Cancer Precision Imaging Agents: Diagnostic radiopharmaceutical imaging agents designed for gallium-68 and fluorine-18 positron emission tomography scanning to detect and localize primary and metastatic prostate cancer during staging and restaging procedures across hospital networks.
- Brain and Renal Cancer Imaging Candidates: Positron emission tomography radiopharmaceutical diagnostic agents engineered with targeted molecular biomarkers to evaluate primary brain gliomas, clear cell renal cell carcinoma, and rare non-urologic tumors.
- Target-Directed Radiotherapeutic Candidates: Late-stage investigational targeted radiopharmaceuticals, including radiolabeled monoclonal antibodies and radio-antibody drug conjugates designed to deliver therapeutic radiation doses directly to metastatic prostate, renal, and bladder cancer cells.
- Medical Technology and Digital Health Solutions: Integrated intraoperative surgical guidance instrumentation, specialized radiopharmaceutical administration software, and artificial intelligence image processing tools that support clinicians in precision treatment planning, delivery, and post-treatment monitoring.
- Contract Radiopharmaceutical Manufacturing Services: Global infrastructure of specialized radiopharmaceutical processing facilities providing isotope production, automated radiopharmaceutical synthesis, cold chain distribution, and regulatory quality management for clinical trial materials and commercial products.
- Fibroblast Activation Protein Targeted Therapeutics: Targeted clinical radiopharmaceutical therapy candidates designed to bind to fibroblast activation protein expressed in tumor microenvironments, addressing advanced or metastatic medullary thyroid carcinoma and selected solid tumors.
Telix Pharmaceuticals executive team
- Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.DCo-Founder, MD, Group CEO & Executive Director
- Mr. Darren Smith B.Bus., FCPA, M.B.A.Group Chief Financial Officer
- Mr. Darren Patti Pharm.D.Group Chief Operating Officer
- Dr. Andreas Kluge M.D., Ph.D.Chief Medical Advisor
- Dr. David N. Cade M.B.A., M.D., MBBSGroup Chief Medical Officer
- Mr. Richard Valeix M.B.A.Chief Executive Officer of Telix Therapeutics
- Dr. Paul SchafferSVP of Research & Development
- Mr. Craig UlrickChief Information Officer
- Ms. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor Relations
- Ms. Lena Moran-Adams L.L.B.Group General Counsel